

Sub B1  
therapeutically significant blood plasma fulvestrant concentration of at least  $2.5\text{ngml}^{-1}$  is attained for at least 2 weeks after injection.

25. The method as claimed in claim 24 wherein the benign or malignant disease is breast cancer.

26. The method as claimed in claim 24 wherein the blood plasma fulvestrant concentration is attained for at least 4 weeks after injection.

27. The method as claimed in claim 24 wherein the blood plasma fulvestrant concentration is attained for 2 to 5 weeks after injection.

B1  
28. A method of treating a benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle whereby the formulation comprises at least  $45\text{mgml}^{-1}$  of fulvestrant.

29. The method as claimed in claim 24 or 28 wherein the pharmaceutical formulation contains 25% w/v or less of a pharmaceutically-acceptable alcohol.

30. The method as claimed in claim 29 wherein the pharmaceutical formulation contains 20% w/v or less of a pharmaceutically-acceptable alcohol.

31. The method as claimed in claim 29 wherein the pharmaceutical formulation contains 15-25% w/v of a pharmaceutically acceptable alcohol.

Sub  
Bl 32. The method as claimed in claim 29 wherein the pharmaceutical formulation contains 17-23%

33. The method as claimed in claim 24 or 28 wherein the pharmaceutical formulation contains 60% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

Bl 34. The method as claimed in claim 33 wherein the pharmaceutical formulation contains 50%w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent .

AT 35. The method as claimed in claim 33 wherein the pharmaceutical formulation contains 45% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

36. The method as claimed in claim 33 wherein the pharmaceutical formulation contains 40% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

37. The method as claimed in claim 33 wherein the pharmaceutical formulation contains 35% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

38. The method as claimed in claim 33 wherein the pharmaceutical formulation contains 30% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

39. The method as claimed in claim 33 wherein the pharmaceutical formulation contains 25% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

40. The method as claimed in claim 33 wherein the pharmaceutical formulation contains 10-25% w/v of a pharmaceutically acceptable non-aqueous ester solvent.

41. The method as claimed in claim 33 wherein the pharmaceutical formulation contains 12-18% w/v of a pharmaceutically acceptable non-aqueous ester solvent.

42. The method as claimed in claim 24 or 28 wherein the pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.

43. The method as claimed in claim 24 or 28 wherein the pharmaceutically-acceptable non-aqueous ester solvent is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

44. The method as claimed in claim 43 wherein the pharmaceutically-acceptable non-aqueous ester solvent is benzyl benzoate.

*Bl*  
*At*  
45. The method as claimed in claim 24 or 28 wherein the total volume of the formulation administered to said human is 6ml or less, and the concentration of fulvestrant in said formulation is at least  $45\text{mgml}^{-1}$ .

46. The method as claimed in claim 24 or 28 wherein the total volume of the formulation administered to said human is 6ml or less, and the total amount of fulvestrant in said volume of formulation is 250mg or more.

47. The method as claimed in claim 46 wherein the total volume of the formulation is from 5 to 5.25ml, the total amount of fulvestrant in said volume of formulation is 250mg.

48. The method as claimed in claim 24 or 28 wherein the pharmaceutically-acceptable alcohol is a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation and the ricinoleate vehicle is castor oil.

*Sub Bl*  
~~49. A method of treating a benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, 15-25% weight of a pharmaceutically-acceptable alcohol per volume of formulation, 10-25 % weight of a pharmaceutically-~~

acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least  $45\text{mgml}^{-1}$  of fulvestrant.

B1  
50. A method of treating a benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, 17-23% weight of a pharmaceutically-acceptable alcohol per volume of formulation, 12-18 % weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least  $45\text{mgml}^{-1}$  of fulvestrant.

---